Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
09:29am, Thursday, 13'th Apr 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. According to these reports, regulators at the FDA
2 Top Growth Stocks That Could Soar This Spring
05:39am, Thursday, 06'th Apr 2023
An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could exte
Sarepta Stock Has $30 to $40 Upside if Panel on Gene Therapy Drug Positive, Says Analyst
12:15pm, Tuesday, 04'th Apr 2023
Citi analyst Neena Bitritto-Garg initiates coverage on shares of Sarepta with a Buy rating.
3 Up-and-Coming Growth Stocks to Buy Right Now
06:00am, Saturday, 25'th Mar 2023
Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.
Why did Sarepta Therapeutics Stock Plummet?
08:01am, Tuesday, 21'st Mar 2023
The middle of March may be when many people celebrate St. Patrick's Day, but it was an unlucky time for Sarepta Therapeutics (NASDAQ: SRPT). Unfortunately, the United States Food and Drug Administrati
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in the Stock?
04:37am, Tuesday, 21'st Mar 2023
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n
Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001
04:02pm, Friday, 17'th Mar 2023
Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.
Why Is Sarepta Therapeutics (SRPT) Stock Down 20% Today?
09:30am, Friday, 17'th Mar 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA. According to a press release, the company will meet with t
Sarepta Crashes On An Unexpected Roadblock For Its Gene Therapy
09:21am, Friday, 17'th Mar 2023
In a surprise decision, the FDA will hold an advisory committee to discuss Sarepta's gene therapy, and SRPT stock tanked Friday. The post Sarepta Crashes On An Unexpected Roadblock For Its Gene Therap
Sarepta Therapeutics plummets 20% after FDA contradicts company and requires advisory meeting
06:16pm, Thursday, 16'th Mar 2023
Sarepta Therapeutics Inc. SRPT shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said it required an advisory committee meet
2 Biotech Stocks To Watch In March 2022
05:52pm, Thursday, 16'th Mar 2023
Check out these 2 biotech stocks in the stock market today.
Sarepta Therapeutics: Time To Change My Game Plan After Q4 Earnings
09:00am, Saturday, 04'th Mar 2023
Sarepta Therapeutics recently reported their Q4 and full-year 2022 earnings with a minor miss on EPS and a solid beat on revenue. The market reacted positively moving SRPT up. The company continues to
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
03:26pm, Thursday, 02'nd Mar 2023
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval.
Sarepta's stock still up after Tuesday's announcement that its Duchenne drug candidate won't require a FDA AdCom meeting
02:45pm, Wednesday, 01'st Mar 2023
Shares of Sarepta Therapeutics Inc. SRPT were up 18.7% in trading on Wednesday afternoon, a day after the company told investors that the Food and Drug Administration does not plan to schedule an advi
Sarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
12:47pm, Wednesday, 01'st Mar 2023
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
